Delcath Systems (DCTH) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.17
- Estimate
- -$0.08
- Surprise
- +319.4%
- Revenue (period 2026-09-30)
- $35.1M
- Score today
- 5.6/10
Revenue source: xbrl.
How the report landed
Delcath Systems (DCTH) beat the -$0.08 estimate with adjusted EPS of $0.17 — a large 319.4% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates DCTH Buy (Wait) at 5.6/10; no pre/post engine snapshot brackets this report.
3 of the last 4 quarters beat the estimate; this quarter's +319.4% surprise compares with a +127.8% four-quarter average.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong earnings beat streak (3/4)
What argues against it
- Concentration risk — Product: HEPZATO
- Concentration risk — Supplier: melphalan supplier
- Thin upside margin: 7.2%
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $21.58
- Entry target
- $20.64
- Price target
- $23.14
- Stop
- $19.20
- Upside to target
- +7.2%
- Reward-to-risk
- 0.5:1
Forward estimates sit below the trailing run-rate (168.9× forward vs 126.7× trailing) — consensus expects earnings to decline from here.
Risk check: RSI 85 — a level conventionally read as overbought; gains at these levels often lean on momentum; trading volume is running 1.6× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-11-10 — shown for context, not personalized investment advice.
DCTH at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Devices
- Market cap
- $703.3M
- P/E (fwd)
- 168.9
- P/E (ttm)
- 126.7
- 52-week range
- $8.12–$20.30
- Off 52-week high
- -6.3%
- RSI (14)
- 85
- Volume vs avg
- 1.59×
- Score today
- 5.6/10